One Piece's Final Saga is finally powering up the Straw Hat Weakling trio after being sidelined in the New World.
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
Phase 2 voting is underway for the 2026 MLB All-Star Game presented by Mastercard. Here's how the races to determine the All-Star starters are shaping up. The finalists at each position in the ...
Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6‑month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally ...
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 10 best AI driven biotech stocks to invest in. On June 3, enrollment for the Phase 1/2 ACHIEVE trial’s registrational expansion cohort, which ...
SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE)-- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Dingwei Ye discussing a phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein ...
AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...
GM1 gangliosidosis, caused by biallelic variants in GLB1, results from deficiency of lysosomal β-galactosidase, which degrades GM1 ganglioside. This fatal neurodegenerative disease currently has no ...
NEO-811 is a novel molecular glue degrader intended to fully block a key clear cell renal cell carcinoma signaling pathway via cereblon-dependent target degradation. The primary outcome measures for ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results